Nurse Practitioner Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Rawahn Saeed

Nurse Practitioner, Primary Care Dearborn Heights, MI Nurse Practitioner

NPI 1306699731 CMS profile 11567636

3902 Monroe St, Dearborn Heights, MI 48125

Open in the dashboard

General payments

$2,163

110 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rawahn Saeed of Dearborn Heights, MI is reported in the CMS Open Payments database as having received $2,163 across 110 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,861 94
2024 General $302 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rawahn Saeed
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Rawahn Saeed were reported at $1,861. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Rawahn Saeed Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $137 $39–$445 $132
2022 $0 $139 $44–$421 $149
2023 $0 $163 $53–$481 $160
2024 $302 $176 $54–$511 $164
2025 $1,861 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. AstraZeneca Pharmaceuticals LP $565 18 payments
  2. AbbVie, Inc. $382 19 payments
  3. GlaxoSmithKline, LLC. $241 15 payments
  4. ITI, Inc. $240 18 payments
  5. Novo Nordisk Inc $169 9 payments
  6. Axsome Therapeutics, Inc. $85 4 payments
  7. Lundbeck LLC $81 5 payments
  8. Otsuka America Pharmaceutical, Inc. $70 4 payments
  9. Lilly USA, LLC $66 4 payments
  10. Pfizer Inc. $61 4 payments
  11. Other $203 10 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $2,163 110 payments
Products named General payments · program years 2024–2025
  1. VRAYLAR Neuroscience $263 13 payments
  2. CAPLYTA $220 17 payments
  3. AIRSUPRA $182 4 payments
  4. TRELEGY ELLIPTA $162 14 payments
  5. Ozempic $116 6 payments
  6. RYBELSUS $98 5 payments
  7. VRAYLAR Neuroscience $93 4 payments
  8. REXULTI Psychiatry $81 5 payments
  9. AREXVY $79 1 payment
  10. REXULTI Psychiatry $70 4 payments
  11. Other $686 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

356

Median for Nurse Practitioner: 389

Drug cost

$4,647

Median for Nurse Practitioner: $21,885

Branded share of claims

18.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lidocaine Generic 19 $1,446
Albuterol Sulfate Hfa Albuterol Sulfate Brand 21 $730
Hydroxyzine Hcl Generic 13 $471
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 32 $401
Fluticasone Propionate Generic 21 $246
Omeprazole Generic 17 $227
Atorvastatin Calcium Generic 23 $175
Ibuprofen Generic 13 $163
Levothyroxine Sodium Generic 14 $137
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 14 $98

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $93
$93 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $35
$35 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $31
$31 — —
REXULTI
  • Lundbeck LLC $31
$31 — —
CAPLYTA
  • ITI, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

110 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record